The treatment of choroidal neovascularisations with intravitreal injections of bevacizumab (Avastin®)

Klinische Monatsblatter fur Augenheilkunde

Volumn 225, Issue 5, 2008, Pages 380-384

  Valmaggia, Christophe ^a   Niederberger, H ^a   Lang, C ^a   Kloos, P ^a   Haueter, I ^a  

^a Kantonsspital St Gallen ^*  (Switzerland)

Author keywords

Choroidal neovascularisation; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; OFLOXACIN; POVIDONE IODINE; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ABNORMAL SENSATION; ADULT; AGED; ARTICLE; BLURRED VISION; CARDIOMYOPATHY; CEREBROVASCULAR ACCIDENT; CONJUNCTIVAL HEMORRHAGE; CORNEA ABRASION; DEEP VEIN THROMBOSIS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOPHTHALMITIS; FATALITY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOREIGN BODY SENSATION; HEART INFARCTION; HUMAN; INTRAOCULAR FOREIGN BODY; LENS DISEASE; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; RETINA DETACHMENT; SUBRETINAL NEOVASCULARIZATION; UVEITIS; VISUAL ACUITY; VITREOUS HEMORRHAGE; ADOLESCENT; INTRALESIONAL DRUG ADMINISTRATION; MIDDLE AGED; TREATMENT OUTCOME; VITREOUS BODY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FEMALE; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MIDDLE AGED; TREATMENT OUTCOME; VITREOUS BODY;

EID: 47649099848     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1027266     Document Type: Article

References (31)

1. Avery RL, Pieramici DJ, Rabena MD et al. Intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363-372
2. Bermig J, Tylla H, Jochmann C et al. Angiographic findings in patients with exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2002; 240: 169-175
3. Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001; 119: 198-207
4. Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444
5. Falkenstein IA, Cheng L, Morrison VL et al. Standardized visual acuity results associated with primary versus secondary bevacizumab treatment for choroidal neovascularization in age-related macular degeneration. Retina 2007; 27: 701-706
6. Gragoudas ES, Adamis AP, Cunningham ET. Pegabtanib for neovascular age-related macular degeneration. N Engl J Med 2004; 350: 2335-2342
7. Heier JS, Boyer DS, Ciulla TA FOCUS study group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 2006; 124: 1532-1542
8. Hahn R, Sacu S, Michels S et al. Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macula degeneration. Ophthalmologe 2007; 104: 588-593
9. Hurwitz H, Fehrenbacher L, Novotny W. Bevacizumab plus irnotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342
10. Itturalde D, Spaide RF, Meyerle CB. Intravitreal bevacizumab treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006; 26: 279-284
11. Jonas JB, Spandau UH, Rensch F et al. Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. J Ocul Pharmacol Ther 2007; 2: 240-242
12. Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Laser Imaging 2006; 37: 144-146
13. Kernt M, Welge-Lüssen U, Yu A et al. Bevacizumab is not toxic to human anterior- and posterior-segment cultured cells. Ophthalmologe 2007; E-pub (in German)
14. Laud K, Spaide RF, Freund KB. Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 2006; 26: 960-963
15. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmacother 2007; 41: 614-625
16. Mason JO, Albert MA, Mays A et al. Regression of neovascular iris vessels by intravitreal injection of bevacizumab. Retina 2006; 26: 839-841
17. Manzano RP, Peyman GA, Khan P et al. Testing intravitreal toxicity of bevacizumab. Retina 2006; 26: 262-269
18. Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab treatment. Retina 2006; 26: 270-274
19. Michels S, Rosenfeld PJ, Puliafito CA et al. Systemic bevacizumab therapy for neovascular age-related macular degeneration. Ophthalmology 2005; 112: 1035-1047
20. Quiroz-Mercado H, Ustariz-Gonzales O, Martinez-Castellanos MA et al. Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story. Seminars in Ophthalmology 2007; 22: 109-125
21. Raftery J, Clegg A, Jones J et al. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol 2007; 91: 1244-1246
22. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36: 331-335
23. Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431
24. Sakaguchi H, Ikuno Y, Gomi F. Intravitreal injection of bevacizumab for choroidal neovascularization associated with pathological myopia. Br J Ophthalmol 2007; 91: 161-165
25. Silva PJ, Jorge R, Alves CR. Short-term results of intravitreal bevacizumab on anterior segment neovascularization in neovascular glaucoma. Acta Ophthalmol Scand 2006; 84: 556-557
26. Slakter JS, Bochow TW, D'Amico DJ. Anecortave acetate versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology 2006; 11: 3-13
27. Spaide RF, Fisher YL. Intravitreal bevacizumab treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006; 26: 275-278
28. van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promise and potential problems. JAMA 2005; 293: 1509-1513
29. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H et al. Twelve-month safety of intravitreal injections of bevacizumab: results of the pan-american collaborative retina study group. Graefes Arch Clin Exp Ophthalmol 2007; Epub
30. Yamamoto I, Rogers AH, Reichel E. Intravitreal bevacizumab as treatment for subfoveal choroidal neovascularization secondary to pathologic myopia. Br J Ophthalmol 2007; 91: 157-160
31. Ziemssen F, Lüke M, Messias A et al. Safety monitoring in bevacizumab treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients. Int Ophthalmol 2007; Epub